TY - CHAP M1 - Book, Section TI - Drug-induced Pulmonary Disease Due to Nonchemotherapeutic Agents A1 - Cain, Hilary C. A2 - Grippi, Michael A. A2 - Antin-Ozerkis, Danielle E. A2 - Dela Cruz, Charles S. A2 - Kotloff, Robert M. A2 - Kotton, Camille Nelson A2 - Pack, Allan I. PY - 2023 T2 - Fishman’s Pulmonary Diseases and Disorders, 6e AB - Medications have long been recognized as having the potential to cause pulmonary injury even when given at therapeutic doses. The precise incidence of drug-induced respiratory disease is difficult to ascertain and potentially is confounded by reporting bias for positive events; the signs and symptoms of lung toxicity are shared by many other pulmonary conditions and diseases. Data on adverse events are supplied to national databases such as the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Event Report (JADER), and these databases can be utilized to determine patterns and incidence of events. However, these databases are limited by data input, and concerns inevitably are raised about the completeness and accuracy of direct submissions from providers and healthcare facilities compared with those from drug manufacturers.1,2 As the categories and varieties of therapeutic drugs continue to increase, clinicians will encounter disease from new culprit drugs in addition to well-established drug reactions. A web-based data repository, Pneumotox V2.2 (www.pneumotox.com), is a useful tool for the clinician, as it provides frequent updates based on the emerging literature on drug-induced respiratory toxicities. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1195007021 ER -